Navigation Links
The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients

t data and treatment protocols every two years.

VELCADE has been available to patients, who have relapsed after a previous treatment, in the United States since 2003 and in Europe since 2004. VELCADE as a single agent shows a median overall survival in this patient population of two and a half years (29.8 months) with "robust response rates" regardless of age. VELCADE in combination with DOXIL(R) was approved in May 2007. Data from a follow-up to a Phase 3 multi-national clinical trial shows that this combination further improves the probability of survival by 41%. Among the findings presented from an open label Phase I/II study evaluating 54 patients, when VELCADE is combined with melphalan and prednisone in newly diagnosed patients who do not go on to have transplants, survival was 85% the strongest 3 year survival rate demonstrated to date.

REVLIMID, an oral drug, is the newest of the novel therapies. This is the first conference since its European approval earlier this month; it is already approved in the United States for use in combination with dexamethasone as a treatment for multiple myeloma in patients who have been previously treated. Among the findings presented, in patients who have relapsed or not responded to a previous treatment, the 35 month median survival using REVLIMID in combination with dexamethasone has been characterized as the "highest response rate and longest overall survival" reported so far from two large randomized controlled Phase III trials that enrolled more than 700 patients worldwide. Importantly, it was previously reported that in patients newly diagnosed with multiple myeloma, in a large randomized Phase III trial evaluating more than 400 patients, REVLIMID with low dose dexamethasone demonstrated what has been called an "unprecedented" 98% one year survival in patients under 65 and 95% one year survival in patients 65 and over.

Combining these two powerful agents, VELCADE AND REVLIMID, produces "robust and du
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
Post Your Comments:
(Date:9/16/2014)... , Sept. 16, 2014  Denovo Biopharma, LLC, ... late-stage oncology drug, from Eli Lilly and Company ... manufacture and commercialize enzastaurin globally, including transfer of ... information. Lilly developed enzastaurin in ... and Phase 3 clinical trials for diffuse large ...
(Date:9/16/2014)... Wash. , Sept. 16, 2014 /PRNewswire/ ... a late stage development company engaged primarily ... medical isotopes for diagnostic and therapeutic applications, ... for technology related to its brachytherapy products.  ... arise from its license from Battelle, under ...
(Date:9/16/2014)... -- Russia,s pharmaceutical ... Pharma 2020 Strategy provides incentives for local producers to ... foreign markets. These trends, however, were affected by recent ... political and economic sanctions imposed on Russia ... Russia responded to the US ...
Breaking Medicine Technology:Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 2Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 3Advanced Medical Isotope Corporation Licensed Brachytherapy Seed Patent Granted 4Global Medicines for Russia 2
(Date:9/17/2014)... Irvington, NY (PRWEB) September 17, 2014 ... youth sports, concussion prevention is top of mind ... developed five facts to remember about concussions and ... Treatment, developed for kids, parents, coaches and teachers ... , "As a pediatric orthopedic ...
(Date:9/17/2014)... Lee Berman, a seasoned veteran of ... on The Balancing Act® airing on Lifetime Television®. Berman ... segment will premiere on September 19 and re-air on ... on Lifetime Television®' with show host Julie Moran. Berman ... over a decade and is the Director of Marketing ...
(Date:9/17/2014)... Freeslate, Inc. , the leading ... development, today announced that Baylor University acquired a ... to both support Baylor research interests and provide ... throughput system is expected to significantly accelerate innovation ... for small molecule organic chemistry. , The ...
(Date:9/17/2014)... Presence Technology, a multinational provider ... Suite 10.0, which incorporates significant enhancements to meet ... , The Contact Center Agents and Supervisors will ... get a better feel for the performance of ... and who requires additional coaching or mentoring to ...
(Date:9/16/2014)... BamboofloorChina.com, the popular online supplier of elegant bamboo items, ... bamboo floors to its product catalogue. Along with ... new items; the current discount is up to 27 ... season. Therefore, BamboofloorChina.com spares no energy to offer more ... items offered by BamboofloorChina.com are in stock and ready ...
Breaking Medicine News(10 mins):Health News:Video Helps Kids and Adults Talk About Concussion Recognition and Treatment 2Health News:Lee Berman Will Appear On The Balancing Act® airing on Lifetime Television® 2Health News:Baylor University Selects Freeslate Reaction Screening System to Support New High Throughput Screening Lab 2Health News:Presence Technology’s 10.0 Release Drives Contact Center Web Supervisor Effectiveness While Reducing Operation Costs and Delivering Enterprise Grade Scalability 2Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2
... VIEJO, Calif., Sept. 19 Clarient, Inc.,(Nasdaq: CLRT ... and the pharmaceutical industry, today announced,that it is scheduled ... Life Sciences Conference at 4:30 p.m. EDT on Wednesday, ... Grand Hyatt in New York City,September 24-27. A ...
... /Xinhua-PRNewswire-FirstCall/ -- To help buyers,identify suppliers offering ... GSOL ) and Bureau Veritas, one ... have launched the B2B industry,s,most comprehensive supplier ... ) Co-developed by the two companies, ...
... volunteers representing the Women,s Dermatologic Society (WDS) will, help ... free skin cancer screenings and sun safety ... PLANO, Texas, Sept. 18 Even though higher altitudes,mean ... balloon,enthusiasts enjoying the upcoming Plano Hot Air Balloon Festival ...
... following statement today on proposed legislation by Senators,Kent Conrad ... to create a,task force to reform Social Security and ... the most successful safety,nets in our nation and any ... be done by the committees of jurisdiction in Congress; ...
... and other tissue in the laboratory in conditions similar to ... The technology, developed and patented by scientists at Durham University ... which allows cells to be grown in a more realistic ... a Petri dish. , Evidence gathered by the research ...
... ELMHURST, Ill., Sept. 18 Secure Services Corp. ... Parke has joined,them as the Director of Business ... northwest suburbs for 22 years. He was an,acknowledged ... of the National Conference of Insurance Legislators (NCOIL). ...
Cached Medicine News:Health News:Clarient to Present at the UBS 2007 Global Life Sciences Conference 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 2Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 3Health News:Supplier Assessments to Help Buyers Identify Reliable China Exporters 4Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 2Health News:Sun Safety Outreach to Families Takes Flight at the Plano Hot Air Balloon Festival 3Health News:Cell growth technology promises more successful drug development 2Health News:Cell growth technology promises more successful drug development 3Health News:Former State Representative Terry Parke Joins Secure Services Corp. 2
... thin collagen coated highly compliant ... thin wall construction offers optimal ... Hemacarotid UltraThin Patch provides superb ... and healing, without suture hole ...
The VasoSeal Low Profile device is designed for smaller sheath angiography procedures. VasoSeal Low Profile. Seal your arterial punctures with confidence....
D-Stat Radial is a dry version of the D-Stat together with a compression band, and is designed for the control of surface bleeding from vascular access sites, including the sites on the radial artery...
... engineered to close arteriotomies with ease ... with a simple trigger actvated mechanism, ... deliver sheath gently locks onto the ... the site before, during, and after ...
Medicine Products: